Bioventus第三季度节拍激增

2025-11-05 01:36

Bioventus (BVS) is up ~19% in Tuesday trading after posting Q3 financial results that beat on both lines.
While net sales change year-over-year was essentially flat due to a ~29% decline in its restorative therapies segment, the medical device company saw strong growth of, respectively, 6.4% and 9.3%, in its two largest businesses, pain treatments and surgical solutions, to ~$67.2M and ~$50.2M.
Pain treatment growth was driven by U.S. demand for Durolane, a hyaluronic acid therapy for knee osteoarthritis, while surgical solutions benefitted from US demand for bone graft substitutes and ultrasonics.
The quarter's non-GAAP EPS of $0.15 compares to $0.05 in the year-ago period.
Bioventus ended the quarter (Sept. 27) with cash and cash equivalents of $42.2M compared to ~$41.6M on Dec. 31, 2024.

More on Bioventus